{"id":68291,"date":"2026-06-16T14:13:28","date_gmt":"2026-06-16T06:13:28","guid":{"rendered":"https:\/\/flcube.com\/?p=68291"},"modified":"2026-06-16T14:13:29","modified_gmt":"2026-06-16T06:13:29","slug":"bayer-secures-fda-approval-for-ambelvist-novel-high-relaxivity-mri-contrast-agent-with-lower-gadolinium-dose","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68291","title":{"rendered":"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted approval for <strong>Ambelvist (gadoquatrane)<\/strong>, a novel intravenous macrocyclic gadolinium-based contrast agent (mGBCA), for use in <strong>adult and pediatric patients (including full-term neonates)<\/strong> undergoing contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with vascular abnormalities in both the <strong>central nervous system (CNS)<\/strong> and <strong>non-CNS body regions<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ambelvist (gadoquatrane) \u2013 tetrameric mGBCA with high relaxivity<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Detection and visualization of vascular abnormality lesions in CNS and body regions<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults and pediatric patients including full-term neonates<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Gadoquatrane \u2013 novel tetrameric macrocyclic gadolinium-based contrast agent<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> Unique tetrameric structure providing high relaxivity (superior signal enhancement)<\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> Effective at 0.01 mmol\/kg (0.04 mmol Gd\/kg) \u2013 significantly lower gadolinium exposure compared to standard agents<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Macrocyclic structure associated with enhanced stability and reduced risk of gadolinium retention<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iii-quanti-study\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase III QUANTI Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Ambelvist (0.04 mmol Gd\/kg)<\/th><th>Standard mGBCAs (0.1 mmol Gd\/kg)<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Lesion Visualization Score<\/strong><\/td><td>Comparable<\/td><td>Reference<\/td><td>Non-inferior<\/td><\/tr><tr><td><strong>Number of Identified Lesions<\/strong><\/td><td>Comparable<\/td><td>Reference<\/td><td>Non-inferior<\/td><\/tr><tr><td><strong>Superiority vs Pre-contrast MRI<\/strong><\/td><td>Significant improvement<\/td><td>N\/A<\/td><td>Met primary endpoint<\/td><\/tr><tr><td><strong>Pediatric Safety<\/strong><\/td><td>Established across all age groups including neonates<\/td><td>N\/A<\/td><td>Comprehensive data package<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pivotal QUANTI study demonstrated that Ambelvist enables superior lesion visualization compared to unenhanced MRI while using a substantially lower gadolinium dose, addressing growing concerns about gadolinium retention in patients requiring repeated contrast-enhanced imaging.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Market:<\/strong> Over 35 million contrast-enhanced MRI procedures performed annually in the US alone, with approximately 40% using gadolinium-based agents<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Ambelvist&#8217;s high relaxivity allows for lower dosing while maintaining diagnostic efficacy, potentially reducing long-term gadolinium accumulation risks<\/li>\n\n\n\n<li><strong>Pediatric Expansion:<\/strong> First mGBCA with comprehensive safety and efficacy data spanning from full-term neonates through adults, opening significant opportunities in pediatric radiology<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project peak annual sales of \u20ac400\u2013600 million globally by 2030, assuming 15\u201320% market share capture in the premium mGBCA segment<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bayer&#8217;s approval of Ambelvist reinforces its leadership position in diagnostic imaging and demonstrates its commitment to developing innovative contrast agents that enhance diagnostic accuracy while prioritizing patient safety through reduced metal exposure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for Ambelvist (gadoquatrane). Actual results may differ due to risks including market adoption, competitive dynamics, reimbursement decisions, and execution of Bayer&#8217;s commercial strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68292,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[269,967],"class_list":["post-68291","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-bayer","tag-etr-bayn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ambelvist (gadoquatrane), a novel intravenous macrocyclic gadolinium-based contrast agent (mGBCA), for use in adult and pediatric patients (including full-term neonates) undergoing contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with vascular abnormalities in both the central nervous system (CNS) and non-CNS body regions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68291\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ambelvist (gadoquatrane), a novel intravenous macrocyclic gadolinium-based contrast agent (mGBCA), for use in adult and pediatric patients (including full-term neonates) undergoing contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with vascular abnormalities in both the central nervous system (CNS) and non-CNS body regions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68291\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T06:13:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T06:13:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose\",\"datePublished\":\"2026-06-16T06:13:28+00:00\",\"dateModified\":\"2026-06-16T06:13:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291\"},\"wordCount\":432,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1603.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68291#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68291\",\"name\":\"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1603.webp\",\"datePublished\":\"2026-06-16T06:13:28+00:00\",\"dateModified\":\"2026-06-16T06:13:29+00:00\",\"description\":\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ambelvist (gadoquatrane), a novel intravenous macrocyclic gadolinium-based contrast agent (mGBCA), for use in adult and pediatric patients (including full-term neonates) undergoing contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with vascular abnormalities in both the central nervous system (CNS) and non-CNS body regions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68291\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68291#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ambelvist (gadoquatrane), a novel intravenous macrocyclic gadolinium-based contrast agent (mGBCA), for use in adult and pediatric patients (including full-term neonates) undergoing contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with vascular abnormalities in both the central nervous system (CNS) and non-CNS body regions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68291","og_locale":"en_US","og_type":"article","og_title":"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose","og_description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ambelvist (gadoquatrane), a novel intravenous macrocyclic gadolinium-based contrast agent (mGBCA), for use in adult and pediatric patients (including full-term neonates) undergoing contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with vascular abnormalities in both the central nervous system (CNS) and non-CNS body regions.","og_url":"https:\/\/flcube.com\/?p=68291","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T06:13:28+00:00","article_modified_time":"2026-06-16T06:13:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68291#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68291"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose","datePublished":"2026-06-16T06:13:28+00:00","dateModified":"2026-06-16T06:13:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68291"},"wordCount":432,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68291#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1603.webp","keywords":["Bayer","ETR: BAYN"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68291#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68291","url":"https:\/\/flcube.com\/?p=68291","name":"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68291#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68291#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1603.webp","datePublished":"2026-06-16T06:13:28+00:00","dateModified":"2026-06-16T06:13:29+00:00","description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for Ambelvist (gadoquatrane), a novel intravenous macrocyclic gadolinium-based contrast agent (mGBCA), for use in adult and pediatric patients (including full-term neonates) undergoing contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with vascular abnormalities in both the central nervous system (CNS) and non-CNS body regions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68291#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68291"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68291#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1603.webp","width":1080,"height":608,"caption":"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68291#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Secures FDA Approval for Ambelvist \u2013 Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68291"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68291\/revisions"}],"predecessor-version":[{"id":68293,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68291\/revisions\/68293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68292"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}